Cost-Effectiveness and Cost-Utility of the Adherence Improving self-Management Strategy (AIMS) in HIV-Care: A Trial-Based Economic Evaluation

Ben F. M. Wijnen (Corresponding Author), Edwin J. M. Oberjé, Silvia M. A. A. Evers, Jan M. Prins, Hans-Erik Nobel, Cees van Nieuwkoop, Jan Veenstra, Frank J. Pijnappel, Frank P. Kroon, Laura van Zonneveld, Astrid G. W. Van Hulzen, Marjolein van Broekhuizen, Marijn de Bruin

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

Objectives: Several promising HIV-treatment adherence interventions have been identified, but data about their cost-effectiveness is lacking. This study examines the trial-based cost-effectiveness and costutility of the proven-effective Adherence Improving self-Management Strategy (AIMS), from a societal
perspective, with 15 months’ time horizon.
Methods: Treatment-naïve, and treatment-experienced patients at-risk for viral rebound were randomized to treatment-as-usual (TAU) or AIMS in a multi-center randomized controlled trial, in the Netherlands. AIMS is a nurse-led, 1-on-1 self-management intervention incorporating feedback from electronic medication monitors, delivered during routine clinical visits. Main outcomes were costs per reduction in log10 viral load, treatment failure (two consecutive detectable viral loads), and qualityadjusted life years.
Results: 223 patients were randomized. From a societal perspective, AIMS was slightly more expensive than TAU but also more effective, resulting in an ICER of €549 per reduction in log10 viral load and €1,659 per percentage decrease in treatment failure. In terms of QALYs, AIMS resulted in higher costs but more QALYs compared to TAU, which resulted in an ICER of €27,759 per QALY gained. From a healthcare perspective, AIMS dominated TAU. Additional sensitivity analyses addressing key limitations of the base case analyses also suggested that AIMS dominates TAU.
Conclusions: The base case analyses suggests that over a period of 15 months, AIMS may be costlier, but also more effective than TAU. All additional analyses suggest that AIMS is cheaper and more effective than TAU. This trial-based economic evaluation confirms and complements a model-based economic evaluation with a life-time horizon showing that AIMS is cost-effective.
Original languageEnglish
Pages (from-to)658-667
Number of pages10
JournalClinical Infectious Diseases
Volume68
Issue number4
Early online date14 Sep 2018
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • adherence
  • intervention
  • HIV/AIDS
  • cost effectiveness
  • cost-utility
  • Adherence
  • Intervention
  • Cost-effectiveness
  • Cost-utility
  • VIRAL LOAD
  • cost-effectiveness
  • MULTICENTER
  • FORM HEALTH SURVEY
  • TREATMENT OUTCOMES
  • HIV-INFECTED PATIENTS
  • INTERVENTIONS
  • ACTIVE ANTIRETROVIRAL THERAPY
  • NONADHERENCE
  • QUESTIONNAIRE
  • MEDICATION ADHERENCE

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Cost-Effectiveness and Cost-Utility of the Adherence Improving self-Management Strategy (AIMS) in HIV-Care: A Trial-Based Economic Evaluation'. Together they form a unique fingerprint.

  • Cite this

    Wijnen, B. F. M., Oberjé, E. J. M., Evers, S. M. A. A., Prins, J. M., Nobel, H-E., van Nieuwkoop, C., Veenstra, J., Pijnappel, F. J., Kroon, F. P., van Zonneveld, L., Van Hulzen, A. G. W., van Broekhuizen, M., & de Bruin, M. (2019). Cost-Effectiveness and Cost-Utility of the Adherence Improving self-Management Strategy (AIMS) in HIV-Care: A Trial-Based Economic Evaluation. Clinical Infectious Diseases, 68(4), 658-667. https://doi.org/10.1093/cid/ciy553